NALIRIFOX
Phase 3Small molecule
NALIRIFOX is one of 195 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 3.
6
Indications
10
Total Trials
10
Active Trials
194
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
335 competitors in Pancreatic Cancer
#DrugCompanyPhaseTrials
1NALIRIFOX
TTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase 3
Byetta
AstraZenecaPreclinical
Ayvakit Sprinkle
MMemorial Sloan Kettering Cancer Center
Preclinical
MS Contin
HHikma Pharmaceuticals LLC
Preclinical
Xylocaine
MMEDRx USA, Inc.
Preclinical
Feraheme
AAzurity Pharmaceuticals
Preclinical
Active Comparator
ModernaPreclinical
Sulfonylureas
Eli LillyPreclinical
Neoadjuvant Treatment
SShanghai Zhongshan Hospital
Preclinical
Cyclophosphamid
EEssen Biotech
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Pancreatic Ductal Adenocarcinoma3 trials
Pancreatic Cancer1 trial
Pancreatic Adenocarcinoma1 trial
Neoadjuvant Therapy1 trial
Neoadjuvant Therapy （NALIRIFOX） for Locally Advanced Colon and Upper Rectal Cancer
Active, not recruiting·—·Phase 4·NCT07020468·57 enrolled
3 more indications
Adult Subject1 trial
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Recruiting·TTheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)·Phase 1·NCT06917079·387 enrolled
Neuroendocrine Neoplasm1 trial
Pancreatic Ductal Adenocarcinoma (PDAC)1 trial
Clinical Study of Radiotherapy Combined With Adebrelimab and NALIRIFOX for Conversion Therapy in Locally Advanced Pancreatic Cancer
Not yet recruiting·SShanghai General Hospital, Shanghai Jiao Tong University School of Medicine·Phase 2·NCT07827053·36 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NALIRIFOX. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details